

IntelGenx Technologies Corp.  
Form 8-K  
August 22, 2016

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
Washington, DC 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of the Securities and Exchange Act of 1934**

Date of Report (Date of earliest event reported): **August 22, 2016**

**IntelGenx Technologies Corp.**

(Exact name of registrant as specified in its charter)

Delaware  
(State or other jurisdiction of  
incorporation)

000-31187  
(Commission File No.)

87-0638336  
(IRS Employer ID)

**6420 Abrams, Ville Saint Laurent, Quebec, H4S 1Y2 Canada**

(Address of principal executive offices and Zip Code)

**(514) 331-7440**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events - News Release**

**IntelGenx Announces Successful Clinical Study for Montelukast for the Treatment of Degenerative Diseases of the Brain**

Exhibit Description

99.1 Press Release

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**INTELGEX TECHNOLOGIES CORP.**

Dated: August 22, 2016

By: */s/ Horst Zerbe*  
Horst G. Zerbe  
President and Chief Executive Officer